Trial 0C-23-26


A Phase 1 Study of NM32-2668 (Anti-ROR1 / Anti-CD3/ Anti-HSA Tri- Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jacob Thomas, M.D.
Other Trial Staff:  Yan Ning, D.M., Lorraine Martinez, Coordinator, Nicole Jensen, Coordinator, Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Negeen Izadian, Coordinator, Clara Karam, D.M., Nazeli Livaskani, Coordinator, Bomi Choi, Coordinator, Brianna Olea, Coordinator, Marc Cruz, D.M., Stephanie Kim, Coordinator, Maura Fernandez, D.M., Teshia Bustos, D.M., Alexandra Artura, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.